MedTrace Logo

Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.

NCT01983657 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-11-18

No results posted yet for this study

Summary

The purpose of this study is to establish an efficient and economic treatment scheme by evaluation of the safety and efficacy of subcutaneous injection of low-dose rhGM-CSF, or of similar injection after whole lung lavage , in patients with PAP.

Conditions

  • Pulmonary Alveolar Proteinosis

Interventions

DRUG

rhGM-CSF

GM-CSF will be given subcutaneously according to the rule in different groups.

PROCEDURE

Whole Lung Lavage(WLL)

using double lumen endotracheal tube (DLT) to selectively lavage one lung

Sponsors & Collaborators

  • Shanghai Pulmonary Hospital, Shanghai, China

    lead OTHER

Principal Investigators

  • Huiping Li, Dr · Shanghai Pulmonary Hospital, Shanghai, China

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
17 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-06-30
Completion
2014-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01983657 on ClinicalTrials.gov